{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-313400","form_type":"8-K","ticker":"IKT","cik":"0001750149","company_name":"Inhibikase Therapeutics, Inc.","filed_at":"2026-07-23T12:32:45+00:00","discovered_at":"2026-07-23T12:35:00.436483+00:00","generated_at":"2026-07-23T12:35:04.196094+00:00","sec_items":["7.01","9.01"],"event_type":"regulatory","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Inhibikase Therapeutics receives FDA Orphan Drug Designation for IKT-001 in PAH","bullets":["FDA granted Orphan Drug Designation to IKT-001 (prodrug of imatinib mesylate) for Pulmonary Arterial Hypertension.","PAH affects approximately 50,000 people in the United States; ODD provides tax credits, fee exemptions, and 7-year exclusivity upon approval.","CEO Mark Iwicki cited pre-clinical data at ATS showing improved vascular markers and lower GI toxicity vs. imatinib mesylate.","ODD applies to the active moiety imatinib, not a specific formulation, per FDA's Office of Orphan Products Development."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-313400","json":"https://secwatch.observer/filing/0001193125-26-313400.json","markdown":"https://secwatch.observer/filing/0001193125-26-313400.md","text":"https://secwatch.observer/filing/0001193125-26-313400.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1750149/000119312526313400/0001193125-26-313400-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1750149/000119312526313400/d121491d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-07-23T12:35:04.196094+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}